Pine Labs shares rise over 4% after Q4 results. Why Morgan Stanley forecasts 67% upside
Pine Labs shares surged after the company reported a significant turnaround, posting a Rs 59 crore net profit in Q4FY26 against a loss last year. Full-year profits also swung to Rs 113 crore. Despite a recent share price dip, Morgan Stanley mainta...

Revenue from operations during Q4FY26 rose 17% year-on-year to Rs 701 crore from Rs 599 crore reported in the corresponding quarter of the previous financial year. On a sequential basis, profit after tax increased 40% from Rs 42 crore posted in Q3FY26, even as revenue declined nearly 6% from Rs 744 crore recorded in the October-December quarter.
For the full financial year FY26, the company posted revenue of Rs 2,711 crore compared with Rs 2,274 crore in FY25, reflecting a growth of 19%. The company also swung to a profit of Rs 113 crore during the year, against a loss of Rs 145 crore in the previous financial year.
Pine Labs share price: Buy, sell, hold?
Morgan Stanley has maintained its “Equal-weight” rating on Pine Labs with a target price of Rs 245, an upside of 67%. The brokerage noted that Q4 revenue growth of 17% year-on-year came in around 3% below consensus estimates, while adjusted EBITDA rose 73% year-on-year but was marginally below expectations.
Management has guided for medium-term revenue growth of 21-23.5%. Morgan Stanley highlighted that the issuing and acquiring business continued to post strong growth of 24% year-on-year, while flow, affordability and transaction processing GTV increased 44% year-on-year.
Pine Labs shares are down 24% in the last 1 month and about 36% since the beginning of the year. The fintech company made a strong debut on the BSE on November 14,, listing at Rs 242 per share, a 9.5% premium over its IPO price of Rs 221.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Download ET Markets APP